

# HOUSE BILL 1549

J1, J2

7lr0133

---

By: **Chair, Health and Government Operations Committee (By Request – Departmental – Health and Mental Hygiene)**

Introduced and read first time: February 16, 2017

Assigned to: Rules and Executive Nominations

---

## A BILL ENTITLED

1 AN ACT concerning

2 **Public Health – Drug Overdose Prevention Programs – Revisions**

3 FOR the purpose of authorizing the Department of Health and Mental Hygiene to deny,  
4 suspend, revoke, or refuse to renew a certain registration if a certain applicant or a  
5 certain registrant has surrendered a certain federal registration or fails to meet  
6 certain requirements to obtain a certain registration; authorizing the Department to  
7 limit the scope of a certain initial registration or renewal of a certain registration;  
8 requiring a drug overdose fatality review team to review information on nonfatal  
9 overdoses at a certain meeting; requiring a certain local drug overdose fatality review  
10 team, at the request of the chair of the local team, to be provided access to certain  
11 information and records related to an individual whose near fatality is being  
12 reviewed by the local team; prohibiting the disclosure of identifying information of  
13 or of involvement of an agency with an individual who has experienced an overdose  
14 or of certain individuals related to an individual who has experienced an overdose  
15 during a public meeting of a certain local team; providing that the Overdose  
16 Response Program is to be administered by the Department for a certain purpose;  
17 repealing certain provisions of law relating to the qualifications for, application for,  
18 and issuance of a certificate for completion of a certain educational training program  
19 relating to an opioid overdose; altering the scope of the Program to include the  
20 prescribing and dispensing of other opioid antagonists in addition to naloxone;  
21 authorizing the Department to authorize certain entities to conduct certain  
22 education and training on opioid overdose recognition and response; authorizing an  
23 individual who has received certain education and training to receive from a certain  
24 health care provider a prescription for an opioid antagonist and certain related  
25 supplies; authorizing certain individuals to possess and administer an opioid  
26 antagonist under certain circumstances; authorizing a licensed health care provider  
27 with prescribing authority to prescribe and dispense an opioid antagonist by issuing  
28 a standing order under certain circumstances; authorizing a certain licensed health  
29 care provider who issues a certain standing order to delegate the dispensing of an  
30 opioid antagonist to a certain employee or a certain volunteer under certain

---

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 circumstances; prohibiting certain individuals who administer an opioid antagonist  
2 to a certain individual from being considered to be practicing medicine or registered  
3 nursing; prohibiting an employee or a volunteer of a certain entity who provides an  
4 opioid antagonist to a certain individual from being considered to be practicing  
5 medicine, registered nursing, or pharmacy; defining a certain term; altering certain  
6 definitions; and generally relating to drug overdose prevention programs.

7 BY repealing and reenacting, without amendments,  
8 Article – Criminal Law  
9 Section 5–301(a)(1)  
10 Annotated Code of Maryland  
11 (2012 Replacement Volume and 2016 Supplement)

12 BY repealing and reenacting, with amendments,  
13 Article – Criminal Law  
14 Section 5–307  
15 Annotated Code of Maryland  
16 (2012 Replacement Volume and 2016 Supplement)

17 BY repealing and reenacting, without amendments,  
18 Article – Health – General  
19 Section 5–901  
20 Annotated Code of Maryland  
21 (2015 Replacement Volume and 2016 Supplement)

22 BY repealing and reenacting, with amendments,  
23 Article – Health – General  
24 Section 5–903 through 5–905, 13–3101 through 13–3103, and 13–3107 through  
25 13–3111  
26 Annotated Code of Maryland  
27 (2015 Replacement Volume and 2016 Supplement)

28 BY repealing  
29 Article – Health – General  
30 Section 13–3104 through 13–3106  
31 Annotated Code of Maryland  
32 (2015 Replacement Volume and 2016 Supplement)

33 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,  
34 That the Laws of Maryland read as follows:

35 **Article – Criminal Law**

36 5–301.

1 (a) (1) Except as otherwise provided in this section, a person shall be  
2 registered by the Department before the person manufactures, distributes, or dispenses a  
3 controlled dangerous substance in the State.

4 5–307.

5 (a) Subject to the notice and hearing provisions of § 5–308 of this subtitle, the  
6 Department may deny a registration to any applicant, suspend or revoke a registration, or  
7 refuse to renew a registration if the Department finds that the applicant or registrant:

8 (1) has materially falsified an application filed in accordance with or  
9 required by this title;

10 (2) has been convicted of a crime under federal law or the law of any state  
11 relating to a controlled dangerous substance;

12 (3) has **SURRENDERED FEDERAL REGISTRATION OR** had federal  
13 registration suspended or revoked and may no longer manufacture, distribute, or dispense  
14 a controlled dangerous substance; [or]

15 (4) has violated this title; **OR**

16 **(5) HAS FAILED TO MEET THE REQUIREMENTS FOR REGISTRATION**  
17 **UNDER THIS TITLE OR IN REGULATIONS ADOPTED BY THE DEPARTMENT.**

18 (b) The Department may limit revocation or suspension of a registration to the  
19 particular controlled dangerous substance for which grounds for revocation or suspension  
20 exist.

21 **(C) THE DEPARTMENT MAY LIMIT AN INITIAL REGISTRATION OR THE**  
22 **RENEWAL OF A REGISTRATION TO THE PARTICULAR CONTROLLED DANGEROUS**  
23 **SUBSTANCE FOR WHICH GROUNDS FOR DENIAL OR REFUSAL TO RENEW EXIST.**

24 **Article – Health – General**

25 5–901.

26 In this subtitle, “local team” means the multidisciplinary and multiagency drug  
27 overdose fatality review team established for a county.

28 5–903.

29 (a) The purpose of each local team is to prevent drug overdose deaths by:

1 (1) Promoting cooperation and coordination among agencies involved in  
2 investigations of drug overdose deaths or in providing services to surviving family  
3 members;

4 (2) Developing an understanding of the causes and incidence of drug  
5 overdose deaths in the county;

6 (3) Developing plans for and recommending changes within the agencies  
7 represented on the local team to prevent drug overdose deaths; and

8 (4) Advising the Department on changes to law, policy, or practice,  
9 including the use of devices that are programmed to dispense medications on a schedule or  
10 similar technology, to prevent drug overdose deaths.

11 (b) To achieve its purpose, each local team shall:

12 (1) In consultation with the Department, establish and implement a  
13 protocol for the local team;

14 (2) Set as its goal the investigation of drug overdose deaths in accordance  
15 with national standards;

16 (3) Meet at least quarterly to review the status of drug overdose death  
17 cases **AND INFORMATION ON NONFATAL OVERDOSES**, recommend actions to improve  
18 coordination of services and investigations among member agencies, and recommend  
19 actions within the member agencies to prevent drug overdose deaths;

20 (4) Collect and maintain data as required by the Department; and

21 (5) Provide requested reports to the Department, including:

22 (i) Discussion of individual cases;

23 (ii) Steps taken to improve coordination of services and  
24 investigations;

25 (iii) Steps taken to implement changes recommended by the local  
26 team within member agencies; and

27 (iv) Recommendations on needed changes to State and local laws,  
28 policies, or practices to prevent drug overdose deaths.

29 (c) In addition to the duties specified in subsection (b) of this section, a local team  
30 may investigate the information and records of an individual convicted of a crime or  
31 adjudicated as having committed a delinquent act that caused a death or near fatality  
32 described in § 5-904 of this subtitle.

1 5-904.

2 (a) On request of the chair of a local team and as necessary to carry out the  
3 purpose and duties of the local team, the local team shall be immediately provided with:

4 (1) Access to information and records, including information about physical  
5 health, mental health, and treatment for substance abuse, maintained by a health care  
6 provider for:

7 (i) An individual whose death **OR NEAR FATALITY** is being  
8 reviewed by the local team; or

9 (ii) An individual convicted of a crime or adjudicated as having  
10 committed a delinquent act that caused a death or near fatality; and

11 (2) Access to information and records maintained by a State or local  
12 government agency, including death certificates, law enforcement investigative  
13 information, medical examiner investigative information, parole and probation information  
14 and records, and information and records of a social services agency, if the agency provided  
15 services to:

16 (i) An individual whose death **OR NEAR FATALITY** is being  
17 reviewed by the local team;

18 (ii) An individual convicted of a crime or adjudicated as having  
19 committed a delinquent act that caused a death or near fatality; or

20 (iii) The family of an individual described in item (i) or (ii) of this  
21 item.

22 (b) Substance abuse treatment records requested or provided under this section  
23 are subject to any additional limitations on disclosure or redisclosure of a medical record  
24 developed in connection with the provision of substance abuse treatment services under  
25 State law or 42 U.S.C. § 290DD-2 and 42 C.F.R. Part 2.

26 5-905.

27 (a) Meetings of local teams shall be closed to the public and are not subject to  
28 Title 3 of the General Provisions Article when the local teams are discussing individual  
29 cases of **OVERDOSE OR** drug overdose deaths.

30 (b) Except as provided in subsection (c) of this section, meetings of local teams  
31 shall be open to the public and are subject to Title 3 of the General Provisions Article when  
32 the local team is not discussing individual cases of **OVERDOSE OR** drug overdose deaths.

33 (c) (1) During a public meeting, information may not be disclosed that  
34 identifies:

1 (i) A deceased individual;

2 (II) **AN INDIVIDUAL WHO HAS EXPERIENCED AN OVERDOSE;**

3 [(ii)] (III) A family member, guardian, or caretaker of a deceased  
4 individual **OR OF AN INDIVIDUAL WHO HAS EXPERIENCED AN OVERDOSE;** or

5 [(iii)] (IV) An individual convicted of a crime or adjudicated as  
6 having committed a delinquent act that caused a death or near fatality.

7 (2) During a public meeting, information may not be disclosed about the  
8 involvement of any agency with:

9 (i) A deceased individual;

10 (II) **AN INDIVIDUAL WHO HAS EXPERIENCED AN OVERDOSE;**

11 [(ii)] (III) A family member, guardian, or caretaker of a deceased  
12 individual **OR OF AN INDIVIDUAL WHO HAS EXPERIENCED AN OVERDOSE;** or

13 [(iii)] (IV) An individual convicted of a crime or adjudicated as  
14 having committed a delinquent act that caused a death or near fatality.

15 (d) This section does not prohibit a local team from requesting the attendance at  
16 a team meeting of a person who has information relevant to the team's exercise of its  
17 purpose and duties.

18 (e) A person who violates this section is guilty of a misdemeanor and on conviction  
19 is subject to a fine not exceeding \$500 or imprisonment not exceeding 90 days or both.

20 13–3101.

21 (a) In this subtitle the following words have the meanings indicated.

22 [(b)] “Advanced practice nurse” has the meaning stated in § 8–101 of the Health  
23 Occupations Article.

24 (c) “Certificate” means a certificate issued by a private or public entity to  
25 administer naloxone.

26 (d) “Licensed physician” has the meaning stated in § 14–101 of the Health  
27 Occupations Article.]

1           **(B) “OPIOID ANTAGONIST” MEANS NALOXONE OR ANY OTHER MEDICATION**  
2 **APPROVED BY THE DEPARTMENT THAT IS USED TO COUNTER THE EFFECTS OF AN**  
3 **OPIOID OVERDOSE.**

4           **[(e)] (C)** “Pharmacist” has the meaning stated in § 12–101 of the Health  
5 Occupations Article.

6           **[(f)] (D)** “Private or public entity” means a health care provider, local health  
7 department, community–based organization, substance abuse treatment organization, or  
8 other person that addresses medical or social issues related to drug addiction.

9           **[(g)] (E)** “Program” means an Overdose Response Program.

10           **[(h)] (F)** “Standing order” means a written instruction for the prescribing and  
11 dispensing of [naloxone to a certificate holder] **AN OPIOID ANTAGONIST** in accordance  
12 with § [13–3108] **13–3105** of this subtitle.

13 13–3102.

14           **[An] THE** Overdose Response Program is a program [overseen] **ADMINISTERED** by  
15 the Department for the purpose of providing a means of authorizing certain individuals to  
16 administer [naloxone] **AN OPIOID ANTAGONIST** to an individual experiencing, or believed  
17 to be experiencing, opioid overdose to help prevent a fatality when medical services are not  
18 immediately available.

19 13–3103.

20           (a) The Department shall adopt regulations necessary for the administration of  
21 the Program.

22           (b) The Department may:

23                   (1) Collect fees necessary for the administration of the Program;

24                   (2) [Authorize private or public entities to issue and renew certificates to  
25 persons meeting the requirements of this subtitle;

26                   (3) (i) Authorize private or public entities to conduct [educational]  
27 **EDUCATION AND** training [programs described in § 13–3104 of this subtitle] **ON OPIOID**  
28 **OVERDOSE RECOGNITION AND RESPONSE THAT INCLUDES:**

29                                   **(I) EDUCATION ON RECOGNIZING THE SIGNS AND SYMPTOMS**  
30 **OF AN OPIOID OVERDOSE;**

1                   **(II) TRAINING ON RESPONDING TO AN OPIOID OVERDOSE,**  
2 **INCLUDING THE ADMINISTRATION OF AN OPIOID ANTAGONIST; AND**

3                   **(III) ACCESS TO AN OPIOID ANTAGONIST AND THE NECESSARY**  
4 **SUPPLIES FOR THE ADMINISTRATION OF THE OPIOID ANTAGONIST; [and]**

5                   **[(ii)] (3)**       Develop guidance regarding the content of educational  
6 training programs conducted by private or public entities; and

7                   (4)       Collect and report data on the operation and results of the programs.

8 [13–3104.

9                   (a)       To qualify for a certificate, an individual shall meet the requirements of this  
10 section.

11                   (b)       The applicant shall be at least 18 years old.

12                   (c)       The applicant shall have, or reasonably expect to have, as a result of the  
13 individual's occupation or volunteer, family, or social status, the ability to assist an  
14 individual who is experiencing an opioid overdose.

15                   (d)       (1)       The applicant shall successfully complete an educational training  
16 program offered by a private or public entity authorized by the Department.

17                   (2)       An educational training program required under this subsection shall:

18                               (i)       Be conducted by:

19                                       1.       A licensed physician;

20                                       2.       An advanced practice nurse;

21                                       3.       A pharmacist; or

22                                       4.       An employee or a volunteer of a private or public entity  
23 who is supervised in accordance with a written agreement between the private or public  
24 entity and a supervisory licensed physician, advanced practice nurse, or pharmacist that  
25 includes:

26   A.       Procedures for providing patient overdose information;

27   B.       Information as to how the employee or volunteer providing  
28 the information will be trained; and



1 C. Standards for documenting the provision of patient  
2 overdose information to patients; and

3 (ii) Include training in:

4 1. The recognition of the symptoms of opioid overdose;

5 2. The proper administration of naloxone;

6 3. The importance of contacting emergency medical services;

7 4. The care of an individual after the administration of  
8 naloxone; and

9 5. Any other topics required by the Department.]

10 [13–3105.

11 An applicant for a certificate shall submit an application to a private or public entity  
12 authorized by the Department on the form that the Department requires.]

13 [13–3106.

14 (a) A private or public entity authorized by the Department shall issue a  
15 certificate to any applicant who meets the requirements of this subtitle.

16 (b) Each certificate shall include:

17 (1) A statement that the holder is authorized to administer naloxone in  
18 accordance with this subtitle;

19 (2) The full name of the certificate holder; and

20 (3) A serial number.

21 (c) A replacement certificate may be issued to replace a lost, destroyed, or  
22 mutilated certificate.

23 (d) (1) The certificate shall be valid for 2 years and may be renewed.

24 (2) In order to renew a certificate, the certificate holder shall:

25 (i) Successfully complete a refresher training program conducted by  
26 an authorized private or public entity; or

27 (ii) Demonstrate proficiency to the private or public entity issuing  
28 certificates under this subtitle.]

1 [13-3107.] **13-3104.**

2 (A) An individual who [is certified] **HAS RECEIVED EDUCATION AND TRAINING**  
3 **IN OPIOID OVERDOSE RECOGNITION AND RESPONSE BY AN AUTHORIZED PRIVATE**  
4 **OR PUBLIC ENTITY** may[:

5 (1) On presentment of a certificate,] receive from any licensed [physician  
6 or advanced practice nurse] **HEALTH CARE PROVIDER** with prescribing authority a  
7 prescription for [naloxone] **AN OPIOID ANTAGONIST** and the necessary supplies for the  
8 administration of [naloxone;] **THE OPIOID ANTAGONIST.**

9 (B) **AN INDIVIDUAL FOR WHOM AN OPIOID ANTAGONIST IS PRESCRIBED AND**  
10 **DISPENSED TO IN ACCORDANCE WITH THIS SUBTITLE MAY:**

11 [(2)] (1) Possess A prescribed [naloxone] **OPIOID ANTAGONIST** and the  
12 necessary supplies for the administration of [naloxone] **THE OPIOID ANTAGONIST;** and

13 [(3)] (2) In an emergency situation when medical services are not  
14 immediately available, administer [naloxone] **AN OPIOID ANTAGONIST** to an individual  
15 experiencing or believed by the [certificate holder] **INDIVIDUAL** to be experiencing an  
16 opioid overdose.

17 [13-3108.] **13-3105.**

18 [(a) A licensed physician or an advanced practice nurse with prescribing authority  
19 may prescribe and dispense naloxone to a certificate holder.

20 (b) A registered nurse may dispense naloxone to a certificate holder in a local  
21 health department if the registered nurse complies with:

22 (1) The formulary developed and approved under § 3-403(b) of this article;  
23 and

24 (2) The requirements established under § 8-512 of the Health Occupations  
25 Article.]

26 [(c)] (A) (1) A licensed [physician or an advanced practice nurse] **HEALTH**  
27 **CARE PROVIDER** with prescribing authority may prescribe and dispense [naloxone to a  
28 certificate holder] **AN OPIOID ANTAGONIST** by issuing a standing order if the licensed  
29 [physician or advanced practice nurse] **HEALTH CARE PROVIDER:**

30 (i) Is employed by the Department or a local health department; or

1 (ii) Supervises or conducts [an educational] **EDUCATION AND**  
2 training [program under § 13–3104(d) of this subtitle] **ON OPIOID OVERDOSE**  
3 **RECOGNITION AND RESPONSE IN ACCORDANCE WITH A WRITTEN AGREEMENT WITH**  
4 **AN AUTHORIZED PRIVATE OR PUBLIC ENTITY UNDER § 13–3103 OF THIS SUBTITLE.**

5 (2) A licensed [physician or an advanced practice nurse] **HEALTH CARE**  
6 **PROVIDER** with prescribing authority who issues a standing order under paragraph (1) of  
7 this subsection may delegate **THE DISPENSING OF AN OPIOID ANTAGONIST** to [the  
8 following persons the authority for dispensing naloxone to a certificate holder:

9 (i) A licensed registered nurse who:

- 10 1. Is employed by a local health department; and  
11 2. Completes a training program approved by the  
12 Department; and

13 (ii) An] **AN** employee or a volunteer of [a] **AN AUTHORIZED** private  
14 or public entity [who is authorized to conduct an educational training program in  
15 accordance with § 13–3104(d) of this subtitle] **IN ACCORDANCE WITH A WRITTEN**  
16 **AGREEMENT BETWEEN THE DELEGATING LICENSED HEALTH CARE PROVIDER AND**  
17 **THE AUTHORIZED PRIVATE OR PUBLIC ENTITY THAT EMPLOYS THE EMPLOYEE OR**  
18 **VOLUNTEER.**

19 (3) Any licensed health care provider who has dispensing authority also  
20 may dispense [naloxone to a certificate holder] **AN OPIOID ANTAGONIST TO ANY**  
21 **INDIVIDUAL** in accordance with a standing order issued by a licensed [physician] **HEALTH**  
22 **CARE PROVIDER WITH PRESCRIBING AUTHORITY IN ACCORDANCE WITH THIS**  
23 **SUBSECTION.**

24 [(d)] **(B)** [(1)] Any licensed health care provider who has prescribing authority  
25 may prescribe [naloxone] **AN OPIOID ANTAGONIST** to a patient who is believed by the  
26 licensed health care provider to be at risk of experiencing an opioid overdose or in a position  
27 to assist an individual at risk of experiencing an opioid overdose.

28 [(2)] A patient who receives a naloxone prescription under paragraph (1) of  
29 this subsection is not subject to the training requirements under § 13–3104(d) of this  
30 subtitle.]

31 [(e)] **(C)** A pharmacist may dispense naloxone in accordance with a therapy  
32 management contract under Title 12, Subtitle 6A of the Health Occupations Article.

33 [13–3109.] **13–3106.**

1 (a) [(1) A certificate holder] **AN INDIVIDUAL** who, in accordance with this  
2 subtitle, is administering [naloxone] **AN OPIOID ANTAGONIST** to an individual  
3 experiencing or believed by the [certificate holder] **INDIVIDUAL** to be experiencing an  
4 opioid overdose may not be considered to be practicing:

5 [(i)] **(1)** Medicine for the purposes of Title 14 of the Health  
6 Occupations Article; or

7 [(ii)] **(2)** Registered nursing for the purposes of Title 8 of the Health  
8 Occupations Article.

9 [(2)] **(B)** An employee or volunteer of a private or public entity who, in  
10 accordance with this subtitle, provides [naloxone to a certificate holder] **AN OPIOID**  
11 **ANTAGONIST TO AN INDIVIDUAL WHO HAS RECEIVED EDUCATION AND TRAINING IN**  
12 **OPIOID OVERDOSE RECOGNITION AND RESPONSE** in accordance with a standing order  
13 may not be considered to be practicing:

14 (i) Medicine for the purposes of Title 14 of the Health Occupations  
15 Article;

16 (ii) Registered nursing for the purposes of Title 8 of the Health  
17 Occupations Article; or

18 (iii) Pharmacy for the purposes of Title 12 of the Health Occupations  
19 Article.

20 [(b)] **(C)** [(1)] A licensed [physician] **HEALTH CARE PROVIDER WITH**  
21 **PRESCRIBING AUTHORITY** who prescribes or dispenses [naloxone to a certificate holder  
22 in a manner consistent with the protocol established by the authorized private or public  
23 entity] **AN OPIOID ANTAGONIST IN ACCORDANCE WITH THIS SUBTITLE** may not be  
24 subject to any disciplinary action **BY THE APPROPRIATE LICENSING HEALTH**  
25 **OCCUPATIONS BOARD** under [Title 14 of] the Health Occupations Article solely for the  
26 act of prescribing or dispensing [naloxone to the certificate holder] **AN OPIOID**  
27 **ANTAGONIST**.

28 [(2) An advanced practice nurse with prescribing authority who prescribes  
29 or dispenses naloxone to a certificate holder in a manner consistent with the protocol  
30 established by the authorized private or public entity may not be subject to any disciplinary  
31 action under Title 8 of the Health Occupations Article solely for the act of prescribing or  
32 dispensing naloxone to the certificate holder.]

33 [13-3110.] **13-3107.**

34 (a) An individual who administers [naloxone] **AN OPIOID ANTAGONIST** to an  
35 individual who is or in good faith is believed to be experiencing an opioid overdose shall

1 have immunity from liability under §§ 5–603 and 5–629 of the Courts and Judicial  
2 Proceedings Article.

3 (b) A cause of action may not arise against any licensed [physician, advanced  
4 practice nurse] **HEALTH CARE PROVIDER** with prescribing authority[,] or pharmacist for  
5 any act or omission when the [physician, advanced practice nurse with] **LICENSED**  
6 **HEALTH CARE PROVIDER WITH** prescribing authority[,] or pharmacist in good faith  
7 prescribes or dispenses [naloxone] **AN OPIOID ANTAGONIST** and the necessary  
8 paraphernalia for the administration of [naloxone to a certificate holder] **THE OPIOID**  
9 **ANTAGONIST TO AN INDIVIDUAL** or patient under § [13–3108] **13–3105** of this subtitle.

10 (c) This subtitle may not be construed to create a duty on any individual to:

11 (1) Obtain [a certificate] **EDUCATION AND TRAINING IN OPIOID**  
12 **OVERDOSE RECOGNITION AND RESPONSE** under this subtitle, and an individual may  
13 not be held civilly liable for failing to obtain [a certificate] **EDUCATION AND TRAINING IN**  
14 **OPIOID OVERDOSE RECOGNITION AND RESPONSE** under this subtitle; or

15 (2) Administer [naloxone] **AN OPIOID ANTAGONIST** to an individual who  
16 is experiencing or believed by the individual to be experiencing an opioid overdose.

17 [13–3111.] **13–3108.**

18 A person who dispenses [naloxone] **AN OPIOID ANTAGONIST** in accordance with  
19 this subtitle is exempt from any laws that require a person to maintain a permit to dispense  
20 prescription drugs.

21 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect  
22 October 1, 2017.